APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers’s disease

Journal Article (2026)
Author(s)

Jesper Qvist Thomassen (Copenhagen University Hospital – Rigshospitalet)

Hampton Leonard (National Institute on Aging)

Brittany Ulms (University of Oxford)

Benjamin Grenier-Boley (LabEx DISTALZ - U1167-RID-AGE Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement)

Pablo Garcia-Gonzalez (Universitat Internacional de Catalunya, Universidad Pontificia Comillas)

Sami Heikkinen (University of Eastern Finland - Joensuu Campus)

Atahualapa Castillo-Morales (Cardiff University)

Masataka Kikuchi (University of Tokyo)

N. Tesi (Vrije Universiteit Amsterdam, TU Delft - Electrical Engineering, Mathematics and Computer Science, Amsterdam Neuroscience)

More Authors (External organisation)

Research Group
Pattern Recognition and Bioinformatics
DOI related publication
https://doi.org/10.1038/s41588-026-02713-9 Final published version
More Info
expand_more
Publication Year
2026
Language
English
Research Group
Pattern Recognition and Bioinformatics
Journal title
Nature Genetics
Issue number
10
Volume number
58
Pages (from-to)
2474-2484
Page Views
25
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E (APOE) gene ɛ2/ɛ3/ɛ4 polymorphisms remain the longstanding benchmark for genetic disease risk with a consistently large effect across studies1,2,3,4,5,6,7,8,9,10. Despite this massive signal, the exact mechanisms by which ɛ4 increases and ɛ2 decreases dementia risk remain poorly understood. Notably, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers11,12,13, hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. HP1BP3, SLC50A1, PTPRC, NPAS3, DDHD1, CHST9, SMYD2, PRAMEF1 and GFRA1 emerged as new genomic signals for AD risk, appearing only when stratified by APOE carrier status. DDHD1 appeared especially promising, showing protective effects in ε4 carriers, being identified as an expression quantitative trait locus and being involved in rare neuronal diseases. Such APOE-stratified insights may help understand and overcome side effects, inform clinical trial enrollment strategies, and create the scientific basis for targeted, mechanism-driven therapies in neurodegenerative diseases.